MedCity News
JULY 12, 2022
PharmStars, a digital health accelerator, graduated its latest cohort of startups, each of them developing a solution addressing some aspect of neurological disease. The accelerator is accepting applications for the next group of startups for the fall program. The theme is innovations in real-world evidence.
Medgadget
JULY 12, 2022
Researchers at the RIKEN Center for Biosystems Dynamics Research in Japan have developed an AI-powered robotic system that can perform laboratory experiments in regenerative medicine, learn from the results, and perform iterative rounds of experimentation to achieve a certain goal. In a proof-of-principle, the researchers set the robot the task of optimizing cell culture conditions to create a maximal number of retinal pigment epithelium (RPE) cells.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
JULY 12, 2022
New company Areteia Therapeutics launched with up to $350 million in financing and an asthma drug candidate from Knopp Biosciences. That drug, dexpramipexole, previously failed a pivotal test in amyotrophic lateral sclerosis but more recent clinical testing found that the way the small molecule works has applications in eosinophilic asthma, a severe form of the respiratory disease.
Pharmaceutical Technology
JULY 12, 2022
Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of biotechnology company ViaCyte in a deal totalling $320m in cash. ViaCyte focuses on offering new stem cell-derived cell replacement therapies as a functional cure for type 1 diabetes (T1D). Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
MedCity News
JULY 12, 2022
Moving Analytics, a telehealth startup that provides remote cardiac rehab, raised $20 million in Series A funding. It will use the funds to scale its platform, expand its presence in the market and develop content focusing on heart health among women and people of color.
European Pharmaceutical Review
JULY 12, 2022
According to a recent survey of patient groups, Roche, Pfizer, ViiV Healthcare and Gilead Sciences are among the top companies for implementing and reporting progress on environmental, social, governance (ESG) activities. However the survey of 1,500 patient groups also found that 55 percent were not aware of pharma’s ESG programmes, suggesting pharma needs to better include and consider the patient perspective in establishing their ESG goals.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Scott Burrows
JULY 12, 2022
Where Has Your Motivation Gone? As a former sales advisor with 20 years of experience as a motivational sales speaker, I have an important question: What do you do, when all your motivation has gone? For any salesperson, no matter the field, a lack of motivation is not a luxury.
European Pharmaceutical Review
JULY 12, 2022
Microbes developing resistance to disinfectants is a major emerging problem in pharmaceutical manufacturing cleanrooms and, if left unchecked, could present a threat to drug quality and, therefore, human health. More than 480 warning letters solely related to the failure to produce aseptic conditions because of deficient cleaning and disinfection systems for cleanrooms and their equipment, were issued by regulators between 2013 to 2018.
MedCity News
JULY 12, 2022
A new partnership between Yuvo Health, an administrative and managed-care solution for community health centers, and Centene subsidiary Fidelis Care aims to bring value-based care to federally qualified health centers in New York and its Medicaid population.
pharmaphorum
JULY 12, 2022
Going beyond the pill is proving to be a win/win for patients and pharma alike – because improved outcomes are better for everyone. With growing numbers of people around the world living with long-term conditions, the pharmaceutical industry has a golden opportunity to use its expertise to truly enhance lives. But innovative new products are only part of the equation, because even the most efficacious drugs will only work as part of a holistic programme of care that includes mental health suppor
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
European Pharmaceutical Review
JULY 12, 2022
AstraZeneca will acquire all outstanding equity of TeneoTwo for an upfront payment of $100 million on closing. The pharmaceutical giant will make further milestone-related payments of up to $805 million related to R&D and up to $360 million on achievement of commercial milestones. The acquisition of TNB-486 further diversifies AstraZeneca’s haematology pipeline, which spans multiple therapeutic modalities and mechanisms to address a broad spectrum of blood cancers.
Pharmatutor
JULY 12, 2022
FACTOR AFFECTING ON THE DANDRUFF GROWTH AND THE IMPACT OF NATURAL HERBS AS AN ANTI-DANDRUFF AGENT. About Authors. Avdesh Thassu. MPharm.(Nat. Chem.); MBA (Mkt.). Associate Vice President. Global Regulatory Affairs, Emami Limited, 7044455199. athassu@hotmail.com. Chandra Mohan Nandi. MSc.(Med. Chem.). Deputy Manager, Global Regulatory Affairs, Emami Limited, 9051706947. chandramohannandi@yahoo.in. admin.
PharmaVoice
JULY 12, 2022
RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.
Medgadget
JULY 12, 2022
A team at the University of California Davis Health working with international collaborators have developed a new technique to detect typhoid and estimate its incidence in populations over time. The approach requires only a drop of blood from a finger prick and involves measuring levels of antibodies against two antigens: Hemolysin E (Hlye) and Salmonella lipopolysaccharide (LPS).
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
pharmaphorum
JULY 12, 2022
The buoyant financing environment for digital health companies that took off during the pandemic looks like it has come to an end, according to new figures from market watcher Rock Health. The influx of cash that flowed into the sector during the COVID-19 crisis has been followed by a correction that emerged in the first quarter of 2022 and deepened in the second quarter, according to its latest report.
MedReps
JULY 12, 2022
In today’s busy job market, not every candidate receives a follow-up message from an employer letting them know that they didn’t get the job. While some recruiters do have the time to handle these follow-ups, doing so via email or mail, others simply leave the candidates hanging. Thankfully, there’s one thing that candidates can do to increase their chances of getting a job – send a follow-up email after the interview.
MedCity News
JULY 12, 2022
Since we know the fundamental causes of the opioid epidemic, why are we still here? It all centers around stigma.
Medgadget
JULY 12, 2022
Paragonix Technologies , a medtech company based in Massachusetts, created the SherpaPak, an FDA organ transportation device that is intended to keep donor organs safe and viable on their journey to a transplant recipient. As the viability of a donor organ can mean life or death for the receiving patient, it makes sense to take exceptional care of it in transit.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Pharmaceutical Technology
JULY 12, 2022
Health Canada has accepted to review Arcutis Biotherapeutics’ New Drug Submission (NDS) for roflumilast cream 0.3% (ARQ-151) to treat plaque psoriasis in adult and adolescent patients. The Roflumilast cream is a once-a-day topical formulation of the selective phosphodiesterase type 4 (PDE4) inhibitor, roflumilast. A validated target in dermatology, PDE4 is an enzyme that induces overactive immune responses.
Copyright Clearance Center
JULY 12, 2022
The post A Subscription Solution for Emerging Businesses appeared first on Copyright Clearance Center.
Pharmaceutical Technology
JULY 12, 2022
Novavax has signed an agreement with the US Department of Health and Human Services (HHS), in partnership with the Department of Defense, under which the US government will procure 3.2 million doses of the company’s Covid-19 vaccine, NVX-CoV2373, in the initial stage. The order is contingent on the vaccine obtaining Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) as well as the Centers for Disease Control and Prevention (CDC) recommendation.
PharmaTimes
JULY 12, 2022
The partnership will deliver digital therapy support for asthma and COPD patients
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Vodori
JULY 12, 2022
Getting advertising and promotional content to market quickly in support of product and campaign launches is essential for any life science organization. But your ability to get that content to market requires an effective and efficient promotional review process. The less effective your MLR review process, the more time consuming and frustrating it is for your promotional review committee.
PharmExec
JULY 12, 2022
Now Available On Demand! What is key learning? Over 50% of industry forecasters said they would like better access to one key thing. Join us to discuss this important finding and more from our IQVIA Commercial Forecasting Trends Survey.
Pharmaceutical Technology
JULY 12, 2022
The success of chimeric antigen receptor T-cells (CAR-T) in blood cancers has led to the US Food and Drug Administration's (FDA) approval of six products with a pipeline of cell therapies that numbers in the thousands. An analysis of GlobalData’s Pharma Intelligence Centre for cell therapies in major oncology indications in the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan and China) suggests that acute lymphocytic leukaemia (ALL) dominates that pipeline, with mo
pharmaphorum
JULY 12, 2022
La Jolla Pharmaceuticals’ dreams of building a lucrative business from its stable of drugs used in infectious diseases never really paid off, and the company has now sold itself to royalty and asset management firm Innoviva in a deal valued at $149 million. The deal centres on La Jolla’s lead product Giapreza (angiotensin II), used to increase blood pressure in adults with septic shock, and antibiotic Xerava (eravacycline) for complicated intra-abdominal infections (cIAIs), approved
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Pharmaceutical Technology
JULY 12, 2022
Mentions of digitalization within the filings of companies in the pharmaceutical industry fell 38% between the first and second quarters of 2022. In total, the frequency of sentences related to digitalization between July 2021 and June 2022 was 400% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.
pharmaphorum
JULY 12, 2022
Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. Nipah is one of the pathogens that Moderna has identified as the targets of its global public health strategy , an initiative aimed at developing vaccines for 15 infectious diseases that pose the biggest public health risk worldwide.
PharmaTimes
JULY 12, 2022
The lab will allow the Healx team to accelerate the discovery of potential new therapies for more rare conditions
Pharmacy Times
JULY 12, 2022
On this week's episode, Joanna speaks with Carlene Link, PharmD, a clinical pharmacist and integrative life coach, about burnout, managing mental health, and the state of pharmacy.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
144 
Let's personalize your content